Home

Nishan M DeSilva

CIK 1492386 · VP, Finance & Strategy and CFO · last filed 2026-01-06

Nishan M DeSilva is a VP, Finance & Strategy and CFO who has filed 19 SEC Form 4 insider transactions across 4 companies since 2011. The most recent filing, for RNAC, was dated Jan 6, 2026. Across all open-market trades the lifetime net is −$5.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.5M across reported positions. 8 SEC filings were submitted jointly with LIGAND PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.47M

Companies

4

Total Filings

19

Lifetime Open-Market Net

-$5.84M

Filer Profile

Reported Address
11119 NORTH TORREY PINES RD STE 200
LA JOLLA, CA 92037
Related Filers
LIGAND PHARMACEUTICALS INC — 8 joint filings, latest 2015-05-14
JONATHAN S LEFF — 1 joint filings, latest 2010-06-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RNAC Director 11,366 $9.27 $105.4K $0 4 2026-01-06
Cartesian Therapeutics, Inc. (SELB) Delisted Director 7,000 $0.88 $6.2K $20.7K 4 2023-01-04
LGND VP, Finance & Strategy and CFO 22,282 $285.60 $6.36M -$5.86M 7 2015-05-14
ALLOS THERAPEUTICS INC (ALTH) Delisted Director 35,000 — — $0 2 2011-12-15

Recent Filings

19 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-06 RNAC Grant (A) +2,600 $0 EDGAR
2025-01-06 RNAC Grant (A) +2,600 $0 EDGAR
2024-01-04 RNAC Grant (A) +178,000 $0 EDGAR
2023-11-15 RNAC Disp (D) — $0 EDGAR
2023-01-04 Cartesian Therapeutics, Inc. (SELB) Delisted Grant (A) — $0 EDGAR
2022-01-05 Cartesian Therapeutics, Inc. (SELB) Delisted Grant (A) — $0 EDGAR
2021-12-06 Cartesian Therapeutics, Inc. (SELB) Delisted Buy (P) +7,000 $20.7K EDGAR
2021-07-09 Cartesian Therapeutics, Inc. (SELB) Delisted Grant (A) — $0 EDGAR
2015-05-14 LGND Mixed — -$3.33M EDGAR
2015-02-11 LGND Mixed +3,623 -$129.6K EDGAR
Showing 1–10 of 19
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.